News & events

Latest news

Get the latest updates and news from MTM

August 19, 2025

Lucia Bio Raises AU$3M in Seed Financing to Advance Best-in-Class Spleen Tyrosine Kinase (Syk) Inhibitors into Clinical Trial Enabling Studies

Advancing Two Lead Candidates into Formal Development Across Neuroinflammatory & Autoimmune Indications
Read more
March 4, 2025

Curlew Bio Joins MTM’s Brisbane Pod

Uniquest and MTM co-create company to tackle inflammation
Read more
February 11, 2025

Melio Bio Wins 2025 Pioneer Group / Novo Nordisk Golden Ticket

MTM company to Receive Invaluable Support in Driving, Refining Innovation
Read more
November 21, 2024

MTM Achieves Prestigious Great Place to Work Certification

Employees Cite Genuine, People-First Culture
Read more
November 8, 2024

MTM announces Lucia Bio, the first company in the newly established Brisbane pod in collaboration with UniQuest

Developing brain penetrant Syk inhibitors for neurodegenerative conditions
Read more
November 6, 2024

Groundbreaking New Immuno-Oncology Platform to Leverage MTM Bioinformatics

MTM’s work directly contributes to the development of personalized, more effective therapies.
Read more
June 10, 2024

Melio Bio - the first company in the MTM London Pod

Melio Bio, co-created by MTM is focused on the discovery and development of GPCR inhibitors for cardiometabolic disease
Read more
March 25, 2024

MTM named one of the UK’s Best Workplaces™ 2024

We are incredibly proud that we have been named in the top 25 UK’s Best Workplaces™ 2024 List by Great Place To Work®
Read more
September 27, 2023

Pathios Awarded Innovate UK Grant to Evaluate Preclinical Brain Tumor Models

Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer
Read more
September 13, 2023

ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant

ThirtyFiveBio Awarded Innovate UK Biomedical Catalyst Grant
Read more
April 19, 2023

ThirtyFiveBio data debut: AACR 2023 poster presentation

ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference.
Read more
April 19, 2023

Promising Preclinical Data from Research Collaboration with Immunocore

Grey Wolf Therapeutics Reports Promising Preclinical Data from Research Collaboration with Immunocore in Oral Presentation at the American A
Read more
March 28, 2023

Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769

Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
Read more

Upcoming events

Come and meet us, and have a chat to learn more

Mon
12
Jan 2026
JP Morgan Healthcare Conference
San Francisco

The MTM team will be attending JPM, connecting with partners across the global life science ecosystem to propel dealmaking and innovation.

Event details

Transforming lives through collaborative innovation

Contact us
LinkedIn